Table 1 Baseline characteristics between CXCL9-high and CXCL9-low groups
From: CT radiomics prediction of CXCL9 expression and survival in ovarian cancer
Variables | Total (n = 339) | Low (n = 189) | High (n = 150) | p |
|---|---|---|---|---|
Age, n (%) | Â | Â | Â | 0.374 |
 ~ 59 | 175 (52) | 93 (49) | 82 (55) |  |
60 ~  | 164 (48) | 96 (51) | 68 (45) |  |
Chemotherapy, n (%) | Â | Â | Â | 0.925 |
 NO | 21 (6) | 11 (6) | 10 (7) |  |
 YES | 318 (94) | 178 (94) | 140 (93) |  |
Venous_invasion, n (%) | Â | Â | Â | 0.308 |
 NO | 32 (9) | 20 (11) | 12 (8) |  |
 Unknown | 248 (73) | 141 (75) | 107 (71) |  |
 YES | 59 (17) | 28 (15) | 31 (21) |  |
Lymphatic_invasion, n (%) | Â | Â | Â | 0.089 |
 NO | 40 (12) | 25 (13) | 15 (10) |  |
 Unknown | 208 (61) | 122 (65) | 86 (57) |  |
 YES | 91 (27) | 42 (22) | 49 (33) |  |
Tumor_residual_disease, n (%) | Â | Â | Â | 0.696 |
 No Macroscopic disease | 58 (17) | 32 (17) | 26 (17) |  |
 1–10 mm | 162 (48) | 95 (50) | 67 (45) |  |
 10 mm ~  | 86 (25) | 46 (24) | 40 (27) |  |
 Unknown | 33 (10) | 16 (8) | 17 (11) |  |
Histologic_grade, n (%) | Â | Â | Â | 0.83 |
 G1/G2 | 41 (12) | 24 (13) | 17 (11) |  |
 G3/G4/GX | 298 (88) | 165 (87) | 133 (89) |  |
FIGO_stage, n (%) | Â | Â | Â | 0.603 |
 I/II | 19 (6) | 9 (5) | 10 (7) |  |
 III/IV | 320 (94) | 180 (95) | 140 (93) |  |